Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer Clinical research trials and Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer. Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer clinical trial. Participants frequently get the best healthcare available for their Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.

Home > "R" Clinical Trials Conditions > Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer

Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer



Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer

For Condition: radiation toxicity,stage 1 prostate cancer,stage 3 prostate cancer,stage 2 prostate cancer,adenocarcinoma of the prostate
Status: No longer recruiting
Sponsor(s): Arizona Cancer Center ,
Synopsis: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Amifostine may protect normal cells from the side effects of radiation therapy. PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus amifostine in treating patients with primary prostate cancer.
Details: OBJECTIVES: I. Determine the incidence, grade, and time course of acute grade 2 or higher gastrointestinal and genitourinary toxicities in patients with primary prostate adenocarcinoma receiving amifostine plus fractionated radiotherapy. II. Determine the incidence and nature of toxicity associated with amifostine in these patients. III. Assess tumor response to this treatment in these patients. IV. Assess impotency rates following radiotherapy in these patients. PROTOCOL OUTLINE: This is an open label study. Patients receive fractionated radiotherapy five days per week for 7 weeks plus amifostine IV push over 5 minutes, 15 minutes before each radiation treatment. Patients are followed at 1 month after radiotherapy, and then every 3 months for at least 5 years. PROJECTED ACCRUAL: There will be 25 patients accrued into this study over 2 years.
Eligibility:
Study Type:  Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 18 Years/
Genders: 
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed prostate adenocarcinoma; Stage T1a-T3b; N0; M0 disease - PSA at least 10 ng/mL prior to treatment - Must have a risk of seminal vesicle involvement between 10-25% - No palpable or radiographic evidence of seminal vesicle involvement --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: Not specified - Endocrine therapy: Not specified - Radiotherapy: No prior radiotherapy to the prostate area - Surgery: No prior radical prostatectomy - Other: No hypertensive medications if blood pressure less than 120/70 --Patient Characteristics-- - Age: 18 and over - Performance status: Karnofsky 60-100% - Life expectancy: Greater than 24 months - Hematopoietic: Not specified - Hepatic: SGOT and SGOT no greater than 2.5 times upper limit of normal - Renal: Creatinine no greater than 2.0 mg/dL - Cardiovascular: No severe cerebrovascular disease or sustained hypotension not secondary to antihypotensive medication - Other: No history of inflammatory bowel disease; No history of malignancy other than nonmelanoma skin cancer; No underlying medical or psychiatric illness that may impair ability to participate in study
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
JamesOleson,  Study Chair,  Arizona Cancer Center

Arizona Cancer Center
Tucson,  Arizona,  85724
United States
 


Additional Information:
Study ID Numbers:  CDR0000066254;  UARIZ-HSC-9817,NCI-V98-1412,ALZA-98-005-ii
Study Start Date: March 1998
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003307

Other Stage 2 Prostate Cancer Studies:
1. Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

2. Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

3. R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

4. Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

5. Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for High-Risk Stage II or Stage III Prostate Cancer

Related Studies:

Other stage 2 prostate cancer Clinical Trials
Other Arizona Clinical Trials
Other Tucson Clinical Trials

Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer
Modify your Search

  Other stage 2 prostate cancer Clinical Trials
  Other Arizona Clinical Trials
  Other Tucson Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103